Prelude Therapeutics (PRLD)
Prelude Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.1M
Short interest
settlement 2026-10-15
11.5
Days to cover
+3.6 days vs prior
77.0%
Short share of volume
2026-11-02
496
Fails to deliver
settlement 2026-10-09
Wed 11 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PRLD is 5,097,463 shares, up 1,470,894 shares over the last month. Over the last 48 readings it ranged from 510,202 shares (15 August 2025) to 5,097,463 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 444K shares a day that is 11.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/prld" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,097,463 | +11.4% | 444,224 | 11.47 |
| 2026-09-30 | 4,575,044 | +26.1% | 578,215 | 7.91 |
| 2026-09-15 | 3,626,569 | +0.9% | 402,893 | 9.00 |
| 2026-08-31 | 3,593,582 | -5.8% | 643,302 | 5.59 |
| 2026-08-14 | 3,816,602 | +4.0% | 391,381 | 9.75 |
| 2026-07-31 | 3,669,933 | +11.7% | 394,222 | 9.31 |
| 2026-07-15 | 3,286,206 | +16.4% | 344,545 | 9.54 |
| 2026-06-30 | 2,822,240 | +57.4% | 812,143 | 3.48 |
| 2026-06-15 | 1,792,865 | +5.8% | 285,513 | 6.28 |
| 2026-05-29 | 1,693,810 | -8.5% | 315,004 | 5.38 |
| 2026-05-15 | 1,851,622 | +19.1% | 522,874 | 3.54 |
| 2026-04-30 | 1,554,997 | -14.0% | 580,449 | 2.68 |
| 2026-04-15 | 1,807,780 | -22.1% | 348,016 | 5.19 |
| 2026-03-31 | 2,319,677 | +1.9% | 168,502 | 13.77 |
| 2026-03-13 | 2,275,949 | +0.1% | 281,015 | 8.10 |
| 2026-02-27 | 2,272,634 | -4.5% | 364,568 | 6.23 |
| 2026-02-13 | 2,378,569 | +14.7% | 266,633 | 8.92 |
| 2026-01-30 | 2,074,354 | +23.7% | 433,527 | 4.78 |
| 2026-01-15 | 1,677,134 | +13.9% | 539,404 | 3.11 |
| 2025-12-31 | 1,472,870 | +15.1% | 562,003 | 2.62 |
| 2025-12-15 | 1,279,653 | +28.5% | 385,148 | 3.32 |
| 2025-11-28 | 995,838 | -22.1% | 486,122 | 2.05 |
| 2025-11-14 | 1,277,843 | +125.3% | 6,910,800 | 1.00 |
| 2025-10-31 | 567,052 | +10.1% | 268,413 | 2.11 |
| 2025-10-15 | 515,090 | -14.3% | 216,120 | 2.38 |
| 2025-09-30 | 601,130 | +11.7% | 370,485 | 1.62 |
| 2025-09-15 | 538,367 | +1.4% | 132,507 | 4.06 |
| 2025-08-29 | 531,205 | +4.1% | 303,613 | 1.75 |
| 2025-08-15 | 510,202 | -14.2% | 112,626 | 4.53 |
| 2025-07-31 | 594,635 | +14.2% | 136,885 | 4.34 |
| 2025-07-15 | 520,771 | -4.6% | 105,242 | 4.95 |
| 2025-06-30 | 545,657 | -35.1% | 282,288 | 1.93 |
| 2025-06-13 | 841,037 | -11.1% | 176,579 | 4.76 |
| 2025-05-30 | 945,733 | +7.8% | 160,146 | 5.91 |
| 2025-05-15 | 877,740 | -10.3% | 111,121 | 7.90 |
| 2025-04-30 | 978,610 | -56.6% | 118,502 | 8.26 |
| 2025-04-15 | 2,255,923 | -5.2% | 191,746 | 11.77 |
| 2025-03-31 | 2,379,961 | +5.7% | 317,423 | 7.50 |
| 2025-03-14 | 2,252,233 | +4.2% | 171,181 | 13.16 |
| 2025-02-28 | 2,160,583 | -30.4% | 169,072 | 12.78 |
| 2025-02-14 | 3,103,542 | -1.4% | 219,487 | 14.14 |
| 2025-01-31 | 3,149,039 | +1.0% | 254,613 | 12.37 |
| 2025-01-15 | 3,116,988 | -7.8% | 273,909 | 11.38 |
| 2024-12-31 | 3,381,616 | +3.7% | 1,015,062 | 3.33 |
| 2024-12-13 | 3,260,206 | +6.7% | 460,261 | 7.08 |
| 2024-11-29 | 3,056,648 | +5.5% | 309,823 | 9.87 |
| 2024-11-15 | 2,896,842 | -1.6% | 365,199 | 7.93 |
| 2024-10-31 | 2,943,951 | +18.2% | 419,533 | 7.02 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PRLD volume is 77.0%, up 10.2 points over the last five sessions. Over the last 30 readings it ranged from 24.2% (21 October 2026) to 84.7% (29 September 2026). The latest reading is 22.6 points above the 30-session average of 54.4%, on 49K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 38K | 49K | 77.0% | 0 |
| 2026-10-30 | 31K | 54K | 56.5% | 1 |
| 2026-10-29 | 36K | 57K | 62.4% | 0 |
| 2026-10-28 | 74K | 154K | 48.4% | 0 |
| 2026-10-27 | 41K | 86K | 47.9% | 0 |
| 2026-10-26 | 65K | 97K | 66.8% | 0 |
| 2026-10-23 | 39K | 133K | 29.0% | 0 |
| 2026-10-22 | 46K | 181K | 25.5% | 0 |
| 2026-10-21 | 79K | 326K | 24.2% | 0 |
| 2026-10-20 | 51K | 167K | 30.5% | 0 |
| 2026-10-19 | 47K | 110K | 43.0% | 0 |
| 2026-10-16 | 86K | 167K | 51.2% | 2,000 |
| 2026-10-15 | 62K | 178K | 34.8% | 0 |
| 2026-10-14 | 87K | 202K | 43.2% | 0 |
| 2026-10-13 | 147K | 251K | 58.6% | 0 |
| 2026-10-12 | 25K | 48K | 52.2% | 0 |
| 2026-10-09 | 51K | 104K | 48.9% | 0 |
| 2026-10-08 | 52K | 69K | 76.1% | 700 |
| 2026-10-07 | 75K | 186K | 40.3% | 0 |
| 2026-10-06 | 135K | 160K | 84.4% | 0 |
| 2026-10-05 | 66K | 97K | 67.8% | 0 |
| 2026-10-02 | 171K | 344K | 49.7% | 1,197 |
| 2026-10-01 | 109K | 181K | 60.2% | 0 |
| 2026-09-30 | 108K | 137K | 78.9% | 0 |
| 2026-09-29 | 132K | 156K | 84.7% | 0 |
| 2026-09-28 | 77K | 144K | 53.6% | 60 |
| 2026-09-25 | 78K | 113K | 68.7% | 8,399 |
| 2026-09-24 | 158K | 286K | 55.0% | 7,391 |
| 2026-09-23 | 161K | 330K | 48.7% | 7,456 |
| 2026-09-22 | 126K | 201K | 62.7% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in PRLD is 496 shares, up 477 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (13 May 2026) to 393,976 shares (21 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 496 | $3.88 | $2K |
| 2026-10-05 | 19 | $3.67 | $70 |
| 2026-09-29 | 124 | $3.91 | $485 |
| 2026-09-24 | 455 | $4.31 | $2K |
| 2026-09-14 | 114 | $4.59 | $523 |
| 2026-08-31 | 99 | $5.47 | $542 |
| 2026-08-28 | 1,788 | $6.34 | $11K |
| 2026-08-27 | 503 | $6.56 | $3K |
| 2026-08-21 | 8,479 | $6.50 | $55K |
| 2026-08-11 | 360 | $4.83 | $2K |
| 2026-08-04 | 967 | $4.39 | $4K |
| 2026-07-29 | 9,910 | $4.64 | $46K |
| 2026-07-14 | 47 | $4.44 | $209 |
| 2026-07-13 | 15 | $4.81 | $72 |
| 2026-07-09 | 938 | $5.12 | $5K |
| 2026-07-08 | 5,288 | $4.97 | $26K |
| 2026-07-01 | 26 | $5.33 | $139 |
| 2026-06-30 | 234 | $4.93 | $1K |
| 2026-06-17 | 3,527 | $4.20 | $15K |
| 2026-06-16 | 5,411 | $4.46 | $24K |
| 2026-06-15 | 5,618 | $4.49 | $25K |
| 2026-06-10 | 6,725 | $3.94 | $26K |
| 2026-05-22 | 4 | $4.33 | $17 |
| 2026-05-13 | 1 | $4.64 | $5 |
| 2026-04-21 | 393,976 | $4.51 | $1.8M |
| 2026-04-09 | 150 | $4.22 | $633 |
| 2026-04-02 | 147 | $3.45 | $507 |
| 2026-04-01 | 407 | $3.42 | $1K |
| 2026-03-26 | 457 | $3.26 | $1K |
| 2026-03-25 | 89 | $3.12 | $278 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for PRLD in the last 90 days. The most recent filings are listed below. Latest filing: Shah Rajeev M. (TenPercentOwner) on 2026-04-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Shah Rajeev M. | TenPercentOwner | Other transaction | 1.4M | price not stated in the filing | not stated | 6.5M |
| 2026-04-21 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | Buy | 1.1M | $4.44 | $5.0M | 1.1M |
| 2026-04-21 | OrbiMed Genesis GP LLC | Director,TenPercentOwner | Buy | 1.7M | $4.44 | $7.5M | 11.8M |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director, 10% owner | Buy | 1.1M | $4.44 | $5.0M | 1.1M |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director, 10% owner | Buy | 1.7M | $4.44 | $7.5M | 11.8M |
| 2026-04-21 | Bonita David P | Director, 10% owner | Buy | 1.1M | $4.44 | $5.0M | 1.1M |
| 2026-04-21 | Bonita David P | Director, 10% owner | Buy | 1.7M | $4.44 | $7.5M | 11.8M |
| 2025-10-04 | Huang Jane | President, CMO | Tax withholding | 3K | $1.47 | $5K | 87K |
| 2025-10-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 90K |
| 2025-07-04 | Huang Jane | President, CMO | Tax withholding | 3K | $0.79 | $3K | 81K |
| 2025-07-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 84K |
| 2025-04-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 78K |
| 2025-04-04 | Huang Jane | President, CMO | Tax withholding | 3K | $0.68 | $2K | 75K |
| 2025-03-25 | Vaddi Krishna | CEO | Buy | 675K | $0.69 | $466K | 2.0M |
| 2025-03-25 | Combs Andrew | Chief Chemistry Officer | Buy | 100K | $0.69 | $69K | 480K |
| 2025-03-21 | Vaddi Krishna | CEO | Buy | 15K | $0.73 | $11K | 1.3M |
| 2025-03-20 | Vaddi Krishna | CEO | Buy | 5K | $0.73 | $4K | 1.3M |
| 2025-03-17 | Vaddi Krishna | CEO | Buy | 9K | $0.75 | $7K | 1.3M |
| 2025-03-14 | Vaddi Krishna | CEO | Buy | 30K | $0.75 | $22K | 1.3M |
| 2025-03-13 | Vaddi Krishna | CEO | Buy | 50K | $0.72 | $36K | 1.3M |
| 2025-03-12 | Vaddi Krishna | CEO | Buy | 48K | $0.71 | $34K | 1.2M |
| 2025-01-04 | Huang Jane | President, CMO | Tax withholding | 4K | $1.39 | $5K | 69K |
| 2025-01-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 73K |
| 2024-12-31 | Vaddi Krishna | CEO | Buy | 5K | $1.21 | $6K | 143K |
| 2024-12-30 | Vaddi Krishna | CEO | Buy | 10K | $1.20 | $12K | 138K |
| 2024-12-23 | Combs Andrew | Chief Chemistry Officer | Buy | 60K | $1.37 | $82K | 378K |
| 2024-12-20 | Combs Andrew | Chief Chemistry Officer | Buy | 3K | $1.15 | $4K | 318K |
| 2024-12-19 | Vaddi Krishna | CEO | Buy | 7K | $0.89 | $6K | 128K |
| 2024-12-19 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | Buy | 25K | $0.91 | $23K | 27K |
| 2024-12-18 | Vaddi Krishna | CEO | Buy | 100K | $0.93 | $93K | 1.2M |
| 2024-10-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 67K |
| 2024-10-04 | Huang Jane | President, CMO | Tax withholding | 3K | $2.00 | $7K | 63K |
| 2024-07-04 | Huang Jane | President, CMO | Tax withholding | 3K | $3.60 | $12K | 57K |
| 2024-07-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 61K |
| 2024-04-04 | Huang Jane | President, CMO | Tax withholding | 3K | $4.74 | $16K | 51K |
| 2024-04-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 55K |
| 2024-01-04 | Huang Jane | President, CMO | Tax withholding | 4K | $3.77 | $14K | 45K |
| 2024-01-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 49K |
| 2023-10-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 40K |
| 2023-07-04 | Huang Jane | President, CMO | Tax withholding | 3K | $4.65 | $15K | 30K |
| 2023-07-04 | Huang Jane | President, CMO | Exercise or conversion | 9K | price not stated in the filing | not stated | 34K |
| 2023-05-25 | Vaddi Krishna | CEO | Buy | 900 | $5.31 | $5K | 1.1M |
| 2023-05-24 | Lim Bryant David | Chief Legal Officer, Corp Sec. | Buy | 2K | $5.39 | $13K | 2K |
| 2023-05-24 | Vaddi Krishna | CEO | Buy | 1K | $5.01 | $5K | 1.1M |
| 2023-05-23 | Vaddi Krishna | CEO | Buy | 12K | $5.63 | $67K | 1.1M |
| 2023-05-23 | Chardonnet Laurent | Chief Financial Officer | Buy | 5K | $5.50 | $28K | 42K |
| 2023-05-22 | Bonita David P | Director,TenPercentOwner | Buy | 870K | $5.75 | $5.0M | 10.1M |
| 2023-05-22 | ORBIMED CAPITAL LLC | Director,TenPercentOwner | Buy | 870K | $5.75 | $5.0M | 10.1M |
| 2023-04-06 | Huang Jane | President, CMO | Sell | 13K | $6.12 | $81K | 24K |
| 2023-04-04 | Huang Jane | President, CMO | Exercise or conversion | 38K | price not stated in the filing | not stated | 38K |
| 2022-12-20 | Vaddi Krishna | CEO | Buy | 19K | $5.13 | $98K | 121K |
| 2022-12-08 | Chardonnet Laurent | Chief Financial Officer | Buy | 10K | $4.76 | $48K | 36K |
| 2022-06-01 | Chardonnet Laurent | Chief Financial Officer | Buy | 10K | $4.23 | $42K | 25K |
| 2022-03-31 | Combs Andrew | EVP, Head of Chemistry | Exercise or conversion | 36K | $1.89 | $68K | 304K |
| 2022-03-21 | Chardonnet Laurent | Chief Financial Officer | Grant | 7K | $7.51 | $49K | 15K |
| 2021-12-15 | Morosini Deborah | EVP, Chief of Clinical Affairs | Exercise or conversion | 3K | $1.89 | $6K | 3K |
| 2021-12-15 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 29K | $13.00 | $374K | 444 |
| 2021-12-15 | Morosini Deborah | EVP, Chief of Clinical Affairs | Exercise or conversion | 26K | $12.85 | $331K | 29K |
| 2021-12-14 | Combs Andrew | EVP, Head of Chemistry | Buy | 4K | $11.60 | $46K | 268K |
| 2021-12-13 | Vaddi Krishna | President, CEO | Grant | 8K | $12.13 | $97K | 1.1M |
| 2021-12-13 | Chardonnet Laurent | Chief Financial Officer | Grant | 5K | $12.28 | $61K | 8K |
| 2021-12-13 | Combs Andrew | EVP, Head of Chemistry | Buy | 4K | $12.12 | $48K | 264K |
| 2021-11-16 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 28K | $15.87 | $450K | 844 |
| 2021-11-16 | Morosini Deborah | EVP, Chief of Clinical Affairs | Exercise or conversion | 29K | $12.85 | $369K | 29K |
| 2021-11-16 | Morosini Deborah | EVP, Chief of Clinical Affairs | Sell | 400 | $16.43 | $7K | 444 |
| 2021-10-05 | Mauro David J | Chief Medical Officer | Exercise or conversion | 15K | $1.89 | $28K | 15K |
| 2021-10-05 | Mauro David J | Chief Medical Officer | Sell | 6K | $30.26 | $179K | 9K |
| 2021-10-05 | Mauro David J | Chief Medical Officer | Sell | 8K | $31.30 | $244K | 1K |
| 2021-10-05 | Mauro David J | Chief Medical Officer | Sell | 1K | $32.06 | $41K | 0 |
| 2021-09-07 | Mauro David J | Chief Medical Officer | Sell | 5K | $37.79 | $175K | 0 |
| 2021-09-07 | Mauro David J | Chief Medical Officer | Exercise or conversion | 15K | $1.89 | $28K | 15K |
| 2021-09-07 | Mauro David J | Chief Medical Officer | Sell | 7K | $35.91 | $269K | 8K |
| 2021-09-07 | Mauro David J | Chief Medical Officer | Sell | 3K | $36.92 | $106K | 5K |
| 2021-09-02 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 7K | $42.50 | $295K | 4K |
| 2021-09-02 | Pierce Christopher | EVP and Chief of Business Oper | Exercise or conversion | 17K | $12.85 | $218K | 21K |
| 2021-09-02 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 3K | $40.29 | $135K | 17K |
| 2021-09-02 | Pierce Christopher | EVP and Chief of Business Oper | Sell | 7K | $41.52 | $279K | 11K |
| 2021-08-27 | Scherle Peggy | Chief Scientific Officer | Sell | 3K | $36.23 | $98K | 174K |
| 2021-08-27 | Scherle Peggy | Chief Scientific Officer | Sell | 3K | $35.32 | $95K | 176K |
| 2021-08-27 | Scherle Peggy | Chief Scientific Officer | Exercise or conversion | 6K | $1.43 | $9K | 179K |
| 2021-08-27 | Scherle Peggy | Chief Scientific Officer | Sell | 607 | $37.08 | $23K | 173K |
| 2021-08-26 | Scherle Peggy | Chief Scientific Officer | Exercise or conversion | 2K | $1.43 | $2K | 175K |
| 2021-08-26 | Scherle Peggy | Chief Scientific Officer | Sell | 2K | $35.19 | $60K | 173K |
| 2021-08-25 | Piper Brian | Chief Financial Officer | Sell | 4K | $33.23 | $129K | 2K |
| 2021-08-25 | Piper Brian | Chief Financial Officer | Sell | 2K | $32.44 | $68K | 6K |
| 2021-08-25 | Piper Brian | Chief Financial Officer | Exercise or conversion | 8K | $1.89 | $16K | 8K |
| 2021-08-25 | Piper Brian | Chief Financial Officer | Sell | 2K | $34.33 | $80K | 0 |
| 2021-08-13 | Scherle Peggy | Chief Scientific Officer | Sell | 2K | $35.07 | $80K | 173K |
| 2021-08-13 | Scherle Peggy | Chief Scientific Officer | Exercise or conversion | 558 | $1.89 | $1K | 173K |
| 2021-08-13 | Scherle Peggy | Chief Scientific Officer | Exercise or conversion | 2K | $1.43 | $2K | 175K |
| 2021-08-05 | Mauro David J | Chief Medical Officer | Sell | 2K | $31.03 | $64K | 7K |
| 2021-08-05 | Mauro David J | Chief Medical Officer | Sell | 7K | $32.15 | $216K | 100 |
| 2021-08-05 | Mauro David J | Chief Medical Officer | Sell | 100 | $32.63 | $3K | 0 |
| 2021-08-05 | Mauro David J | Chief Medical Officer | Sell | 6K | $29.93 | $183K | 9K |
| 2021-08-05 | Mauro David J | Chief Medical Officer | Exercise or conversion | 15K | $1.89 | $28K | 15K |
| 2021-07-27 | Scherle Peggy | Chief Scientific Officer | Exercise or conversion | 20K | $1.43 | $29K | 193K |
| 2021-07-27 | Scherle Peggy | Chief Scientific Officer | Sell | 680 | $36.09 | $25K | 173K |
| 2021-07-27 | Scherle Peggy | Chief Scientific Officer | Sell | 19K | $35.45 | $685K | 174K |
| 2021-07-06 | Mauro David J | Chief Medical Officer | Sell | 10K | $27.17 | $284K | 5K |
| 2021-07-06 | Mauro David J | Chief Medical Officer | Exercise or conversion | 15K | $1.89 | $28K | 15K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON15 holders report 5% or more of PRLD in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 16.0% of the class (12,935,071 shares), filed 2026-04-23 for an event on 2026-04-21.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-08 | 13G | Levy Guyindividual | 3.4M | 5.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Capital Management, L.P.partnership | 3.4M | 5.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus GP, LLCother entity | 3.4M | 5.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Capital, LLCother entity | 2.7M | 4.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Capital Master Fund, L.P.non-US institution | 2.7M | 4.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Capital Group, LLCother entity | 2.7M | 4.2% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Private Equity GP III, LLCother entity | 676K | 1.0% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus Private Equity Fund III, L.P.partnership | 676K | 1.0% | 2026-04-21 |
| 2026-07-08 | 13G | Soleus PE GP III, LLCother entity | 676K | 1.0% | 2026-04-21 |
| 2026-04-28 | 13G | Rajeev Shahparent holding company, individual | 6.5M | 9.9% | 2026-04-21 |
| 2026-04-28 | 13G | RA Capital Management, L.P.investment adviser, partnership | 6.5M | 9.9% | 2026-04-21 |
| 2026-04-28 | 13G | Peter Kolchinskyparent holding company, individual | 6.5M | 9.9% | 2026-04-21 |
| 2026-04-28 | 13G | RA Capital Healthcare Fund, L.P.partnership | 6.5M | 9.9% | 2026-04-21 |
| 2026-04-23 | 13D/Ano. 3 | ORBIMED ADVISORS LLCinvestment adviser | 12.9M | 16.0% | 2026-04-21 |
| 2026-04-23 | 13D/Ano. 3 | ORBIMED CAPITAL GP VI LLCother entity | 11.8M | 14.6% | 2026-04-21 |
| 2026-04-23 | 13D/Ano. 3 | OrbiMed Genesis GP LLCother entity | 1.1M | 1.4% | 2026-04-21 |
| 2026-04-23 | 13D/Ano. 3 | ORBIMED CAPITAL LLCinvestment adviser | 790K | 1.0% | 2026-04-21 |
| 2026-04-22 | 13D/Ano. 5 | Baker Bros. Advisors LPinvestment adviser, partnership | 10.3M | 15.5% | 2026-04-20 |
| 2026-04-22 | 13D/Ano. 5 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 10.3M | 15.5% | 2026-04-20 |
| 2026-04-22 | 13D/Ano. 5 | Julian C. Bakerindividual, parent holding company | 10.3M | 15.5% | 2026-04-20 |
| 2026-04-22 | 13D/Ano. 5 | Felix J. Bakerindividual, parent holding company | 10.3M | 15.5% | 2026-04-20 |
| 2026-02-13 | 13G/Ano. 6 | Vaddi Krishnaindividual | 6.7M | 13.2% | 2025-12-31 |
| 2025-11-07 | 13G | INCYTE CORPcorporation | 4.4M | 9.9% | 2025-11-03 |
13F holders
Tracked managers holding PRLD at their latest 13F. JSON4 of the 30 tracked managers held PRLD at their latest 13F, $11.4M in total at quarter-end prices. Two Sigma Investments is the largest at $5.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 993K | $5.3M | 0.00% | +70K |
| Millennium Management | 2026-06-30 | 845K | $4.5M | 0.00% | +462K |
| Renaissance Technologies | 2026-06-30 | 281K | $1.5M | 0.00% | +6K |
| Citadel Advisors | 2026-06-30 | 23K | $120K | 0.00% | -102K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Prelude Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Prelude Therapeutics (PRLD), SEC CIK 1678660, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-04-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1678660Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of PRLD is sold short?
5,097,463 shares were held short at the 2026-10-15 settlement, 11.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PRLD's daily short volume?
On 2026-11-02, 37,589 of the 48,811 PRLD shares reported to FINRA were sold short, 77.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PRLD have fails to deliver?
The SEC's latest file shows 496 PRLD shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are PRLD insiders buying or selling?
No open-market insider trades were reported for PRLD in the last 90 days. The most recent filings are listed below. Latest filing: Shah Rajeev M. (TenPercentOwner) on 2026-04-27.
Who owns 5% or more of PRLD?
15 holders report 5% or more of PRLD in their latest filing, 6 on Schedule 13D (active intent). The largest reported stake is ORBIMED ADVISORS LLC at 16.0% of the class (12,935,071 shares), filed 2026-04-23 for an event on 2026-04-21.
Which tracked 13F managers own PRLD?
4 of the 30 tracked 13F managers held PRLD shares at their latest filing, $11.4M in all. The largest: Two Sigma Investments (993K shares, $5.3M), Izzy Englander's Millennium Management (845K shares, $4.5M), Renaissance Technologies (281K shares, $1.5M), Ken Griffin's Citadel Advisors (23K shares, $120K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.